- Home
- KALV vs GLDD Comparison
KALV vs GLDD Comparison
Compare KALV & GLDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- GLDD
- Stock Information
- Founded
- KALV N/A
- GLDD 1890
- Country
- KALV United States
- GLDD United States
- Employees
- KALV N/A
- GLDD N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- GLDD Military/Government/Technical
- Sector
- KALV Health Care
- GLDD Industrials
- Exchange
- KALV Nasdaq
- GLDD Nasdaq
- Market Cap
- KALV 796.4M
- GLDD 770.3M
- IPO Year
- KALV N/A
- GLDD 2006
- Fundamental
- Price
- KALV $13.50
- GLDD $12.14
- Analyst Decision
- KALV Strong Buy
- GLDD Buy
- Analyst Count
- KALV 8
- GLDD 1
- Target Price
- KALV $26.43
- GLDD $14.00
- AVG Volume (30 Days)
- KALV 1.0M
- GLDD 331.4K
- Earning Date
- KALV 09-11-2025
- GLDD 11-04-2025
- Dividend Yield
- KALV N/A
- GLDD N/A
- EPS Growth
- KALV N/A
- GLDD 63.54
- EPS
- KALV N/A
- GLDD 1.06
- Revenue
- KALV $1,426,000.00
- GLDD $830,567,000.00
- Revenue This Year
- KALV N/A
- GLDD $13.73
- Revenue Next Year
- KALV $213.43
- GLDD $3.56
- P/E Ratio
- KALV N/A
- GLDD $11.44
- Revenue Growth
- KALV N/A
- GLDD 24.40
- 52 Week Low
- KALV $7.30
- GLDD $7.51
- 52 Week High
- KALV $17.28
- GLDD $12.89
- Technical
- Relative Strength Index (RSI)
- KALV 44.26
- GLDD 59.19
- Support Level
- KALV $13.26
- GLDD $11.60
- Resistance Level
- KALV $17.28
- GLDD $12.32
- Average True Range (ATR)
- KALV 1.03
- GLDD 0.25
- MACD
- KALV -0.10
- GLDD 0.04
- Stochastic Oscillator
- KALV 9.13
- GLDD 78.82
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.